The European Union has established a centralized system for regulating and approving pharmaceutical drugs. There are three main approval routes: the centralized route administered by the European Medicines Agency, the mutual recognition procedure, and the decentralized procedure. Stringent regulations were implemented following drug safety disasters to protect public health and ensure safe, effective medicines.
Disclaimer:
I have created this document with inputs from various sources. Some are taken right from slideshare. I just try to make this topic little compact and lucid, so that everybody can understand it easily
I am very much thankful to the original authors also, don't think I am just doing plagarism.
plasma master file in European countries and requirements in letter of intent...Sanjay batra
it includes that what is plasma master file, principles, procedure to file PMF, strategy involved, administration information, certification procedure & inspection
Disclaimer:
I have created this document with inputs from various sources. Some are taken right from slideshare. I just try to make this topic little compact and lucid, so that everybody can understand it easily
I am very much thankful to the original authors also, don't think I am just doing plagarism.
plasma master file in European countries and requirements in letter of intent...Sanjay batra
it includes that what is plasma master file, principles, procedure to file PMF, strategy involved, administration information, certification procedure & inspection
It a detailed description of European Union and Medicines and Healthcare Products Regulatory agency with documentation process of filing MAA application.
Medicinal products are highly regulated in the European Union (EU) and are subject to a separate, complicated system of approvals that governs how, when, where, and in what form such products will be allowed to be sold within the borders of the EU.
Pharmaceutical regulatory systems in the EU comprise a decentralized body called the European Medicines Agency (EMA), Heads of Medicines Agencies (HMA), National Competent Authorities (NCAs) and European Directorate for the Quality of Medicines (EDQM). and collection of rules and regulations governing medicinal products in the EU is Eudralex.
The European Medicines Evaluation Agency (EMEA) was established in London, in the year 1995, to coordinate the European Union (EU) member states for evaluating and controlling the medicinal products for both human and veterinary use
The European medicines regulatory system is based on a network of around 50 regulatory authorities from the 31 EEA countries (28 EU Member States plus Iceland, Liechtenstein and Norway)
EMA is responsible for the scientific evaluation, essentially of innovative and high-technology medicines developed by pharmaceutical companies for use in the EU.
EMA has various committees for various categories of medicinal products
Committee for Medicinal Products for Human Use (CHMP)
Pharmacovigilance Risk Assessment Committee (PRAC)
Committee for Medicinal Products for Veterinary Use (CMVP)
Committee for Orphan Medicinal Products (COMP)
Committee on Herbal Medicinal Products (HMPC)
Committee for Advanced Therapies (CAT)
Paediatric Committee (PDCO)
For a medicinal product to seek market authorization in Europe, the manufacturer or sponsor shall choose a pathway from four different pathways based upon the type of medicinal substance, and requirements such as a number of countries chosen for marketing, timeline, etc.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
2. The Europe Union
A political union also called as Europe union formed in 1993 for purpose of achieving political and
economic integration.
The EU includes 28 members states located in Europe.
The EU total population is about 500 millions people.
The EU operates through a system of:
I. Supranational independent institution.
2. Intergovernmental negotiated decisions by its member of the states .
It is legal entity and can negotiate international agreement on behalf of its member states.
In EU there are two regulatory steps by which a drug is approved in market
1. clinical trials application [approved by both member state level].
2. Marketting authorisation [ approved by both member state and centralised level]
3. Pharmaceutical industry is most regulated of all the industries. Regulation are put in order to
develop the most efficient and safe pharmaceutical products. It takes more than 8 to 15 years
to develop a new drug products and costs more than $800 million.
When did this regulation came?
During the 20th century, there were no law’s and regulation to protect public from the
unfavorable effects of the drugs.
Misfortune, disaster and tragedy had triggered most of the advances in drug regulation. There
are some examples of disaster which leads to the formation of regulation in the industry.
*Thalidomide tragedy (1962)
*Elixir sulphanilamide (1937) {taste of death}
Regulation in the Industry
4. The Role of EMA
EMA was established in 1995 to ensure the best use of scientific resources across Europe for
the evaluation, supervision and pharmacovigilance of medicines
EMA is responsible for the scientific evaluation, primarily of innovative and high-technology
medicines developed by pharmaceutical companies for use in the EU.
Experts participate in the work of EMA as members of its scientific committees, working
parties, scientific advisory groups
The experts are chosen on the basis of their scientific expertise and many of them are made
available to EMA by the NCAs in Member States.
Increasingly, patients and healthcare professionals are involved in the work of the Agency
including in the evaluation of medicines.
5. Registration in Europe Post Nov. 2005:
Three European Systems
Centralized Procedure (CP)
(via EMA)
Mutual recognition
procedure
(MRP)
Decentralized procedure
(DCP)
6. Marketing Authorization
To protect public health and ensure the availability
of high quality, safe and effective medicines for
European citizens, all medicines must be authorized
before they can be placed on the market in the EU.
The European system offers different routes for such
an authorization.
7. The centralized procedure : allows the marketing of a medicine on the basis of a
single EU- wide assessment and marketing authorization which is valid throughout the
EU.
Pharmaceutical companies submit a single authorization application to EMA.
The Agency’s committee for medicinal products for human use (CHMP) or committee
for medicinal products for veterinary use (CVMP) then carries out a scientific
assessment of the application and gives a recommendation to the European
commission on whether or not to grant a marketing authorization.
Drug approval in Europe Union
Centralized procedure:
8. Once granted by the European commission, the centralized marketing authorization is
valid in all EU member states. The use of the centrally authorized procedure is
compulsory for most innovative medicines, including medicines for rare diseases.
Rules and Requirements applicable to pharmaceuticals in the EU are the same,
irrespective of the authorization route for a medicine.
A European public Assessment report, (EPAR), is published for every human or
veterinary medicine that has been granted for refused a marketing authorization
following an assessment by EMA.
Drug approval in Europe Union Centralized process is compulsory for:
• Those medicines which are derived from any biotechnology processes, such as genetic
engineering
• Those medicines which are intended for the treatment of Cancer, HIV/AIDS, diabetes,
neurodegenerative disorders or autoimmune diseases and other immune dysfunctions.
• Medicines officially designated 'Orphan medicines' (medicines used for rare diseases).
9. Drug approval in Europe
Union Mutual Recognition
Procedure:
Mutual-recognition procedure where companies that have a medicine
authorised in one EU Member States can apply for this authorisation to be
recognised in other EU countries. This process allows Member States to rely on
each other’s scientific assessments. The Mutual Recognition procedure allows
applicants to obtain a marketing authorization in the concerned member states
(CMS) other Than the Reference member state (RMS), where the drug is
previously approved.
10. • Applicant submits identical dossier to all EU member states in which they want
marketing authorization, including required information.
• As soon as one Member State decides to evaluate the medicinal product (at which point
it becomes the "RMS"), it notifies this decision to other Member States (which then
become the "CMS"), to whom applications have also been submitted.
• RMS issues a report to other states on its own findings
• Generic industry is the major user of this type of drug approval procedure.
• This process may consume a time period of 390 days.
11. Drug approval in Europe Union
Decentralized procedure
The decentralised procedure where companies can apply for the
simultaneous authorisation of a medicine in more than one EU Member State
if it has not yet been authorised in any EU country and does not fall within
the scope of the centralised procedure;
12. Using this procedure, companies may apply for authorization simultaneously in more
than one EU country for products that have not yet been authorized in any EU
country and essentially do not fall within the centralized procedure’s essential drugs
list.
• Based on the assessment report which is prepared by the RMS & any comments
made by the CMS, marketing authorization should be granted in accordance with the
decision taken by the RMS & CMS in this decentralized procedure.
• Generally used for those products that has not yet received any authorisation in an
EU country.
• Time: 210 days.
13. Drug approval in Europe Union
Nationalized Procedure
• The Nationalized procedure is one which allows applicants to obtain a marketing
authorization in one member state only.
• In order to obtain a national marketing authorization, an application must be submitted
to the competent authority of the Member State.
• New active substances which are not mandatory under Centralized procedure can obtain
marketing authorization under this procedure.
• Timeline for this procedure is 210 Days.
14. DCP FLOW CHART
Applicant submits application to the RMS & CMS
RMS & CMS validates the application
RMS distributes the preliminary assessment report to the CMS
RMS sends preliminary assessment report & all comments of the CMS
to the applicant
15. Clock stops, applicant responds, clock runs
RMS sends drafts assessment report to the CMS & applicant
CMS approve the assessment report
Marketing Authorization in RMS & each of the CMS
16. MRP FLOW CHART
Applicant submits application to the RMS & CMS
RMS validates the application
RMS distributes assessment report to the CMS
17. CMS approves the assessment report
CMS Validates the application
Marketing authorization in each of the CMS
18. The European Commission can also take action concerning other aspects of
medicine regulation:
• Right of initiative – it can propose new or amended legislation for the
pharmaceutical sector;
• Implementation – it can adopt implementing measures as well as oversee
the correct application of EU law on pharmaceuticals;
• Global outreach – it ensures appropriate collaboration with relevant
international partners and promotes the EU regulatory system globally.
19. EMA’s scientific committees
The EMA has seven scientific committees that carry out its
scientific assessments:
• Committee for Medicinal Products for Human Use (CHMP)
• Pharmacovigilance Risk Assessment Committee (PRAC)
• Committee for Medicinal Products for Veterinary Use (CMVP)
• Committee for Orphan Medicinal Products (COMP)
• Committee on Herbal Medicinal Products (HMPC)
• Committee for Advanced Therapies (CAT)
• Paediatric Committee (PDCO)
20. NATIONAL COMPETENT AUTHORITIES
The national competent authorities (NCAs), responsible for the regulation of human
and veterinary medicines in the EU, coordinate their work in a forum called Heads
of medicines Agencies (HMA).
The heads of the NCAs work closely with EMA and the European Commission to
maximize cooperation and ensure the European medicines regulatory network
functions efficiently.
The HMA meets four times per year to address key strategic issues for the network,
such as the exchange of information, sharing of best practices, and to streamline
mutual recognition and decentralized procedures.
21. GUIDELINE AND SCIENTIFIC ADVICE
EMA prepares scientific guidelines in cooperation with experts from its scientific
committees and working groups.
These guidelines reflect the latest thinking on developments in biomedical science.
This is an important tool to help develop and make available high quality, effective and
safe medicines, for the benefit of patients.
Scientific advice can also be given by NCAs.
22. SAFETY AND MONITORING OF MEDICINES
The European regulatory system for medicines monitors the safety of all medicines that
are available on the European market throughout their life span.
EMA has a committee dedicated to the safety of medicines for human use – the
Pharmacovigilance Risk Assessment committee, or PRAC.
If there is a safety issue with a medicines that is authorized in more than one member
state, the same regulatory action is taken across the EU and patients and healthcare
professionals in all member states are provided with the same guidance.
23. CLINICAL TRIALS
The authorization and oversight of a clinical trial is the responsibility of the member state in
which the trial is taking place. The European clinical trials database (Eudra CT) tracks which
clinical trials have been authorized in the EU.
It is used by NCAs and clinical-trial sponsors to enter information protocols and results of
clinical trials.
A subset of this information is made publicly available by EMA via the EU clinical trials
register.